JP2022534429A - １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形 - Google Patents

１－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形 Download PDF

Info

Publication number
JP2022534429A
JP2022534429A JP2021570964A JP2021570964A JP2022534429A JP 2022534429 A JP2022534429 A JP 2022534429A JP 2021570964 A JP2021570964 A JP 2021570964A JP 2021570964 A JP2021570964 A JP 2021570964A JP 2022534429 A JP2022534429 A JP 2022534429A
Authority
JP
Japan
Prior art keywords
crystalline polymorph
polymorph
cancer
crystalline
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534429A5 (https=
Inventor
アラン、クーパー
チョーチオン、ウー
シャンミン、コアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of JP2022534429A publication Critical patent/JP2022534429A/ja
Publication of JP2022534429A5 publication Critical patent/JP2022534429A5/ja
Priority to JP2025117422A priority Critical patent/JP2025160244A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021570964A 2019-05-31 2020-05-29 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形 Pending JP2022534429A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117422A JP2025160244A (ja) 2019-05-31 2025-07-11 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855671P 2019-05-31 2019-05-31
US62/855,671 2019-05-31
PCT/US2020/035343 WO2020243584A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117422A Division JP2025160244A (ja) 2019-05-31 2025-07-11 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形

Publications (2)

Publication Number Publication Date
JP2022534429A true JP2022534429A (ja) 2022-07-29
JP2022534429A5 JP2022534429A5 (https=) 2023-06-06

Family

ID=71787116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570964A Pending JP2022534429A (ja) 2019-05-31 2020-05-29 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形
JP2025117422A Pending JP2025160244A (ja) 2019-05-31 2025-07-11 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117422A Pending JP2025160244A (ja) 2019-05-31 2025-07-11 １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形

Country Status (7)

Country Link
US (1) US12378234B2 (https=)
EP (1) EP3976606A1 (https=)
JP (2) JP2022534429A (https=)
CN (1) CN114901655A (https=)
AU (2) AU2020283129A1 (https=)
CA (1) CA3142196A1 (https=)
WO (1) WO2020243584A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2018102453A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12150934B2 (en) 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2018102453A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
""新医薬品の規格及び試験方法の設定について"", 医薬審発第568号, JPN6010021254, 1 May 2001 (2001-05-01), ISSN: 0005342047 *
BERGE，S. M., ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN5004004439, 1977, US, pages 1 - 19, ISSN: 0005342045 *
STEPHEN BYRN ET AL.: ""Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations"", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, JPN5013009960, 1995, pages 945 - 954, ISSN: 0005342051 *
大嶋寛: ""結晶多形・擬多形の析出挙動と制御"", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0005342048 *
山野光久: ""医薬品のプロセス研究における結晶多形現象への取り組み"", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0005342050 *
川口洋子，外２名: ""医薬品と結晶多形"", 生活工学研究, vol. 第４巻第２号, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005342046 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005342049 *

Also Published As

Publication number Publication date
CA3142196A1 (en) 2020-12-03
AU2026201586A1 (en) 2026-03-19
CN114901655A (zh) 2022-08-12
US20220162204A1 (en) 2022-05-26
AU2020283129A1 (en) 2022-02-03
WO2020243584A1 (en) 2020-12-03
US12378234B2 (en) 2025-08-05
EP3976606A1 (en) 2022-04-06
JP2025160244A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
KR101413392B1 (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
CN106170288B (zh) 药物化合物
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
KR102732646B1 (ko) 페닐 트리아졸 mll1-wdr5 단백질-단백질 상호 작용 억제제
JP7853221B2 (ja) ４－アミノ－５－（６－（４－メチルピペラジン－１－イル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－イル）チエノ［２，３－ｂ］ピリジン－６（７ｈ）－オンの塩及び結晶形
JP2019504830A (ja) Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
EA015103B1 (ru) Производные n-фенил-2-пиримидинамина и способ их получения
AU2026201586A1 (en) Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
JP2019512011A (ja) 置換のアミノ６員窒素含有複素環式化合物およびその製造と使用
EP2897952A1 (en) 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CN104045632A (zh) 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用
TWI480276B (zh) 作為蛋白質激酶抑制劑之化合物及組合物
EP2897951A1 (en) 4-indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
HK1260678A1 (en) Salt forms and polymorphs of n-methyl-1h-1,2,3-triazole-4-carboxamide compound
HK1167390B (en) Compounds and compositions as protein kinase inhibitors
HK1191936B (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311